<DOC>
	<DOCNO>NCT00003305</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase II trial study effectiveness aminopterin treat patient refractory leukemia .</brief_summary>
	<brief_title>Aminopterin Treating Patients With Refractory Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose aminopterin patient refractory leukemia minimal previous exposure antifolate agent . II . Determine antileukemic activity aminopterin adult child acute myelogenous acute lymphoblastic leukemia conventional therapy fail . III . Confirm aminopterin administer four consecutive week follow minimal leucovorin calcium rescue determine minimal amount leucovorin calcium require patient . IV . Confirm bioavailability data oral aminopterin perform limited sampling pharmacokinetics . V. Correlate blast uptake aminopterin vitro clinical response . OUTLINE : This open label study . Patients stratify accord age type leukemia : Stratum I : Under 20 year old acute lymphoblastic leukemia ( ALL ) second great relapse Stratum II : Greater 20 year old ALL first great relapse Stratum III : Patients age acute myelogenous leukemia ( AML ) first great relapse Patients receive aminopterin every 12 hour 2 dos weekly 4 week . Aminopterin administer intravenously 20 minute first , second , fourth dos , orally third dose . The fifth subsequent dos administer orally bioavailability acceptable . Patients receive oral leucovorin calcium every 12 hour 2 dos begin 24 hour last dose aminopterin week . If toxicity limit 2 consecutive week , dose leucovorin calcium decrease 1 dose administer 24 hour last dose aminopterin week . If schedule tolerate 2 consecutive week , leucovorin calcium discontinue . Patients continue therapy 15 month absence disease progression unacceptable toxicity . Patients follow every 6 month . PROJECTED ACCRUAL : This study accrue maximum 25 patient per stratum , total 75 patient , within 3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Aminopterin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven acute leukemia histologic type refractory know effective therapy PATIENT CHARACTERISTICS : Age : Any age Performance status : Karnofsky 50100 % Life expectancy : At least 6 week Hematopoietic : Not specify Hepatic : Bilirubin great 1.5 mg/dL ALT great 5 time upper limit normal Renal : Creatinine normal age Cardiovascular : No unstable angina No uncontrolled arrhythmia Pulmonary : No third space effusion Other : No severe uncontrolled infection Adequate nutritional status At least third percentile weight Normal total serum protein Normal albumin/globulin ratio No serious concurrent physical mental illness Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 month since prior bone marrow transplantation Recovered prior biologic therapy No concurrent anticancer biologic therapy Chemotherapy : Recovered prior chemotherapy No concurrent anticancer chemotherapy Endocrine therapy : Recovered prior endocrine therapy No concurrent anticancer endocrine therapy No concurrent dexamethasone steroid antiemetic agent Radiotherapy : No concurrent anticancer radiotherapy Surgery : Not specify Other : No concurrent dairy product 24 hour , , 24 hour study drug No concurrent trimethoprimsulfamethoxazole dapsone prophylaxis Pneumocystis infection No concurrent multivitamins contain folic acid</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
</DOC>